Search - tctmd.com

Displaying 81 - 92 of 92

Sort: Relevancy | Date

Presentation THT 2022

The Role of the Neutrophil to Lymphocyte Ratio as a Predictor of Late Gadolinium Enhancement on Cardiac MRI in Patients With HFpEF

Presenter: Amit Jhaveri

February 01, 2022

News Conference News THT 2022

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Shelley Wood

February 01, 2022

Presentation THT 2022

How to Treat HFpEF in 2022

Presenter: Javed Butler

February 01, 2022

Presentation THT 2022

Molecular Phenotyping

Presenter: Kavita Sharma

February 01, 2022

Presentation THT 2022

Physiological Phenotyping

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

How to Make the Diagnosis

Presenter: Parag Goyal

February 01, 2022

Presentation THT 2022

The Underlying Pathophysiology

Presenter: Greg Lewis

February 01, 2022

Presentation THT 2022

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Long-term follow-up on FIH experience using the Satera Ablation System in HFpEF and HFrEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Overview of the physiology of the splanchnic bed in HFpEF and HFrEF

Presenter: Marat Fudim

February 01, 2022

Presentation THT 2022

Putting it into Perspective: Atrial Shunting in the Context of Current Therapies for HFpEF

Presenter: Scott Solomon

February 01, 2022

Presentation THT 2022

SGLT2 Inhibitors in HFrEF and HFpEF

Presenter: Stefan Anker

February 01, 2022

Advertisement

The Role of the Neutrophil to Lymphocyte Ratio as a Predictor of Late Gadolinium Enhancement on Cardiac MRI in Patients With HFpEF

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

How to Treat HFpEF in 2022

Molecular Phenotyping

Physiological Phenotyping

How to Make the Diagnosis

The Underlying Pathophysiology

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Long-term follow-up on FIH experience using the Satera Ablation System in HFpEF and HFrEF

Overview of the physiology of the splanchnic bed in HFpEF and HFrEF

Putting it into Perspective: Atrial Shunting in the Context of Current Therapies for HFpEF

SGLT2 Inhibitors in HFrEF and HFpEF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content